Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Amplia Therapeutics Limited

Market Cap 5.9Cr 4.14Cr 3.61Cr 3.34Cr 3.13Cr 5.87Cr 390.52Cr 40Cr 15Cr 192.22Cr 16Cr 15Cr 667.44Cr P/E 2027 *
-5x
P/E 2028 * -19.2x
Enterprise Value 4.35Cr 3.05Cr 2.66Cr 2.46Cr 2.31Cr 4.33Cr 287.98Cr 29Cr 11Cr 141.75Cr 11Cr 11Cr 492.19Cr EV / Sales 2027 *
-
EV / Sales 2028 * 3.75x
Free-Float
84.81%
Yield 2027 *
-
Yield 2028 * -
1 day-4.17%
1 week+4.55%
Current month-14.81%
1 month-17.86%
3 months+2.22%
6 months-8.00%
Current year-23.33%
1 week 0.1
Extreme 0.105
0.12
1 month 0.1
Extreme 0.105
0.15
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.42
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 05/12/2022
Director of Finance/CFO - 01/10/2021
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Director/Board Member 70 02/09/2015
Chairman - 25/05/2018
Director/Board Member - 12/04/2021
Date Insider Type Main position Quantity % Market Cap.
08/25/08Buy

Chairman

1,52,174 0.0392%
08/25/08Buy

Chairman

3,36,826 0.0868%
08/25/08Fiscal year

Founder

5,35,000 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%+4.55%-51.06%+38.55% 4.14Cr
+1.44%-1.25%+63.52%+114.88% 5.52TCr
+4.60%+3.02%+58.20%+47.16% 4.58TCr
-1.44%+0.39%-12.94%-19.24% 2.3TCr
-2.69%-2.10%-3.68%+379.00% 2.08TCr
+3.22%-0.84%+27.88%-34.00% 1.63TCr
+0.58%+1.08%+16.73%-38.06% 1.54TCr
-1.01%-2.30%+27.42%+171.92% 1.3TCr
+4.95%+11.70%+123.63%+252.19% 1.24TCr
+3.07%+0.14%+29.37% - 1.24TCr
Average +0.86%+2.46%+27.91%+101.38% 2.14TCr
Weighted average by Cap. +1.63%+1.48%+40.90%+99.90%

Financials

2027 *2028 *
Net sales - 1Cr 70.11L 61.13L 56.62L 53L 99.4L 66Cr 6.72Cr 2.6Cr 33Cr 2.63Cr 2.58Cr 113.07Cr
Net income -1.16Cr -81.33L -70.91L -65.68L -61.48L -1.15Cr -77Cr -7.79Cr -3.02Cr -38Cr -3.05Cr -2.99Cr -131.16Cr -36L -25.24L -22.01L -20.38L -19.08L -35.78L -24Cr -2.42Cr -93.71L -12Cr -94.74L -92.71L -41Cr
Net Debt -1.55Cr -1.09Cr -94.75L -87.76L -82.15L -1.54Cr -102.54Cr -10Cr -4.03Cr -50Cr -4.08Cr -3.99Cr -175.25Cr -2.15Cr -1.51Cr -1.31Cr -1.22Cr -1.14Cr -2.14Cr -142.23Cr -14Cr -5.6Cr -70Cr -5.66Cr -5.54Cr -243.09Cr
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
19/26/19 0.1150 $ -4.17% 4,43,455
18/26/18 0.1200 $ +9.09% 18,27,022
17/26/17 0.1100 $ +4.76% 2,94,142
16/26/16 0.1050 $ -4.55% 14,30,872
15/26/15 0.1100 $ 0.00% 4,93,143
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1150AUD
Average target price
0.4200AUD
Spread / Average Target
+265.22%

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!